Andrew Cummings
April 28, 2017

A total of 3.49 million shares exchanged hands as contrast to its average trading volume of 2.65 million shares.

A number of other equities research analysts also recently issued reports on AKBA. It indicates oversold and overbought price levels for a stock. Akebia Therapeutics has a one year low of $7.00 and a one year high of $13.94.

Some buy side analysts are also providing their Analysis on Akebia Therapeutics, Inc., where 1 analysts have rated the stock as Strong buy, 5 analysts have given a Buy signal, 0 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. Analyst's mean target price for AKBA is $16.33 while analysts mean recommendation is 2.00.

Currently, EPS of Akebia Therapeutics, Inc. WFG Advisors LP now owns 839 shares of the biopharmaceutical company's stock worth $108,000 after buying an additional 739 shares during the last quarter. The Relative Volume value measured for Akebia Therapeutics, Inc. The firm's stock has a market capitalization of $484.75 mln. (AKBA) have 38.78 million outstanding shares now held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders. Finally, Trexquant Investment LP bought a new stake in shares of Akebia Therapeutics during the fourth quarter worth $344,000. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 5.81% with $31.78 Million sitting short, betting on future declines. Fifth Third Financial Bank owns 0% invested in Akebia Therapeutics Inc (NASDAQ:AKBA) for 6,600 shares. Consequently, investors will be able to grasp the rudimentary determinant of asset distribution and all kinds of risk-return parameters for stocks together with the stock mutual funds. The research firm, a unit of Accern, ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time.

The stock's price switched up 36.83% 20-Days Simple Moving Average, added 32.21% from 50-Days Simple Moving Average and rose 39.06% from 200 Days Simple Moving Average.

Akebia Therapeutics (NASDAQ:AKBA) last released its quarterly earnings results on Monday, March 6th.

For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $-0.07 per share according to consensus of 6 analysts. The firm earned $1.54 million during the quarter, compared to the consensus estimate of $125 million. During the same quarter previous year, the firm posted ($0.66) earnings per share. Annual EPS Growth of past 5 years is -29.20%. AKEBIA THERAPEUTICS, INC. (AKBA) has made its way to a 12-month gain of 41.65%.

Akebia Therapeutics, Inc is a biopharmaceutical company.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by BBNS and is owned by of BBNS. Akebia Therapeutics Inc had 14 analyst reports since August 13, 2015 according to SRatingsIntel. Vadadustat is an oral hypoxia-inducible factor (HIF) stabilizer now in Phase 3 development for the treatment of anemia associated with chronic kidney disease (CKD). Its lead product candidate, AKB-6548, is in a Phase 2b clinical trial in patients with anemia secondary to chronic kidney disease who are not dependent on dialysis.

Other reports by iNewsToday